"Even though most urologists who do retroperitoneal surgery do it for posterior tumors, you actually can do it equally well with as equally good success for an anterior tumor," says Michael D. Stifelman, MD.
In this video, Michael D. Stifelman, MD, discusses findings from his study, “A Comparative Analysis of Robot-assisted Retroperitoneoscopic Partial nephrectomy (RARPN) for Anterior vs Posterior Renal tumors: A Propensity Score Matched Analysis in a Multi-Institutional Cohort,” which was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Stifelman is the chair of urology and director of robotic surgery at Hackensack University Medical Center in New Jersey.
Video Transcript:
What we wanted to look at is the use of the retroperineal approach for kidney cancer, and specifically look at the difference in when it's used for a tumor that's posteriorly located, on the back of the kidney, versus anteriorly located, on the front. Everyone we included in our study had a retroperitoneal approach, and again, we then used propensity score matching.
Number one, there was such a difference in the number of cases that were done for posterior tumors versus anterior tumors, as you would expect. Most retroperitoneal approaches are used for a posterior tumor. So, since there was such a difference, we use what's called propensity score matching. We matched it by the size of the tumor, and then a nephrometry score. That way, we could compare equal cohorts to look at if there are any differences when you do an anterior approach retroperitoneally versus a posterior tumor performed retroperitoneally.
What we found was there was no difference. Operative time was the same, blood loss of the same, positive margin rate was not statistically significant, length of stay was the same. What that suggests is that even though most urologists who do retroperitoneal surgery do it for posterior tumors, you actually can do it equally well with as equally good success for an anterior tumor.
This transcription has been edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.